INO
$1.58-0.07 (-4.24%)
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Recent News
PFE Talzenna Combo Shows Strong Efficacy in Wider Prostate Cancer Use
Pfizer's Talzenna/Xtandi combo meets phase III goals, significantly delaying disease progression in HRR-mutated metastatic castration-sensitive prostate cancer patients.
FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April 2026.
Inovio Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
Moby summary of Inovio Pharmaceuticals, Inc.'s Q4 2025 earnings call
Inovio Pharmaceuticals Inc (INO) Q4 2025 Earnings Call Highlights: Strategic Moves and ...
Inovio Pharmaceuticals Inc (INO) navigates financial hurdles and regulatory uncertainties while advancing its DNA medicine platform and preparing for potential product launches.
Inovio Pharmaceuticals Q4 Earnings Call Highlights
Inovio Pharmaceuticals (NASDAQ:INO) management used the company’s fourth-quarter and full-year 2025 earnings call to detail progress on its first biologics license application (BLA), ongoing launch preparations, and cost-cutting actions intended to extend cash runway as the FDA reviews INO-3107 for